常规隐球菌抗原筛查与针对性预防性氟康唑治疗在CD4细胞计数<100/μL的未接受抗逆转录病毒治疗的人类免疫缺陷病毒感染成人中的影响:系统综述与Meta分析
该系统综述与Meta分析纳入31项研究共35644名未接受抗逆转录病毒治疗且CD4细胞计数<100/μL的HIV感染成人,评估血隐球菌抗原(CrAg)阳性率、无症状隐球菌脑膜炎(CM)患病率及筛查后CM发生率与全因死亡率。血CrAg阳性合并患病率为6%(95%CI 5%-7%),CrAg阳性者中无症状CM患病率为33%(95%CI 21%-45%)。未予预防性氟康唑时CM发生率为21.4%(95%CI 11.6%-34.4%),以800 mg/d起始预防性氟康唑治疗时为5.7%(95%CI 3.0%-9.7%);CrAg阳性者全因死亡率仍显著高于CrAg阴性者(风险比2.2,95%CI 1.7-2.9,P<.001)。
要点
- CD4<100/μL未治HIV成人血CrAg阳性合并患病率6%(95%CI 5%-7%)。
- CrAg阳性者中无症状CM患病率33%(95%CI 21%-45%)。
- 预防性氟康唑800 mg/d使CM发生率自21.4%降至5.7%,但CrAg阳性者死亡率仍高于阴性者(风险比2.2)。
核心结论
- 在CD4细胞计数<100/μL的未接受抗逆转录病毒治疗HIV感染成人中,CrAg筛查联合针对性预防性氟康唑似乎有望减轻隐球菌脑膜炎负担。
- CrAg阳性者全因死亡率仍显著高于CrAg阴性者(风险比2.2,95%CI 1.7-2.9,P<.001)。
研究设计与样本
- 系统综述与Meta分析,检索MEDLINE、EMBASE和Web of Science,采用随机效应模型。
- 血CrAg阳性率分析纳入31项研究共35644名参与者。
主要发现
- 血CrAg阳性合并患病率为6%(95%CI 5%-7%)。
- CrAg阳性参与者中无症状CM患病率为33%(95%CI 21%-45%)。
- 未予预防性氟康唑时CM发生率为21.4%(95%CI 11.6%-34.4%),以800 mg/d起始预防性氟康唑治疗时为5.7%(95%CI 3.0%-9.7%)。
- CrAg阳性参与者在起始800 mg/d预防性氟康唑前接受筛查后腰椎穿刺,使CM发生率进一步降至零并显示一定生存获益。
- CrAg阳性者全因死亡率显著高于CrAg阴性者(风险比2.2,95%CI 1.7-2.9,P<.001)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Cryptococcal antigen (CrAg) screening and targeted preemptive fluconazole in antiretroviral-naive human immunodeficiency virus-infected adults with CD4 cell counts <100/μL seems promising as a strategy to reduce the burden of cryptococcal meningitis (CM). We searched MEDLINE, EMBASE, and Web of Science and used random-effect meta-analysis to assess the prevalence of blood CrAg positivity (31 studies; 35644 participants) and asymptomatic CM in CrAg-positive participants and the incidence of CM and the all-cause mortality rate in screened participants. The pooled prevalence of blood CrAg-positivity was 6% (95% confidence interval [CI], 5%-7%), and the prevalence of asymptomatic CM in CrAg-positive participants was 33% (95% CI, 21%-45%). The incidence of CM was 21.4% (95% CI, 11.6%-34.4%) without preemptive fluconazole and 5.7% (95% CI, 3.0%-9.7%) with preemptive fluconazole therapy initiated at 800 mg/d. In CrAg-positive participants, postscreening lumbar puncture before initiating preemptive fluconazole at 800 mg/d further reduced the incidence of CM to null and showed some survival benefits. However, the all-cause mortality rate remained significantly higher in CrAg-positive than in CrAg-negative participants (risk ratio, 2.2; 95% CI, 1.7-2.9; P < .001).
引用
- Temfack E, Bigna JJ, Luma HN, et al. Impact of Routine Cryptococcal Antigen Screening and Targeted Preemptive Fluconazole Therapy in Antiretroviral-naive Human Immunodeficiency Virus-infected Adults With CD4 Cell Counts <100/μL: A Systematic Review and Meta-analysis. Clin Infect Dis. 2019. PMID: 30020446. doi:10.1093/cid/ciy567
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。